CN117298171A - Application of walnut cake extract in preparation of medicine for treating kidney injury - Google Patents
Application of walnut cake extract in preparation of medicine for treating kidney injury Download PDFInfo
- Publication number
- CN117298171A CN117298171A CN202311445684.1A CN202311445684A CN117298171A CN 117298171 A CN117298171 A CN 117298171A CN 202311445684 A CN202311445684 A CN 202311445684A CN 117298171 A CN117298171 A CN 117298171A
- Authority
- CN
- China
- Prior art keywords
- kidney injury
- group
- use according
- extract
- acute kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009496 Juglans regia Nutrition 0.000 title claims abstract description 46
- 235000020234 walnut Nutrition 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 22
- 208000037806 kidney injury Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 240000007049 Juglans regia Species 0.000 title description 2
- 241000758789 Juglans Species 0.000 claims abstract description 44
- 201000011040 acute kidney failure Diseases 0.000 claims abstract description 36
- 208000009304 Acute Kidney Injury Diseases 0.000 claims abstract description 26
- 208000033626 Renal failure acute Diseases 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 210000000582 semen Anatomy 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 7
- 238000010298 pulverizing process Methods 0.000 claims abstract description 7
- 210000005084 renal tissue Anatomy 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 230000010339 dilation Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 claims description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000877 morphologic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 12
- 239000000047 product Substances 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 19
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 15
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 229960000890 hydrocortisone Drugs 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 231100000915 pathological change Toxicity 0.000 description 7
- 230000036285 pathological change Effects 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010039966 Senile dementia Diseases 0.000 description 5
- 208000031975 Yang Deficiency Diseases 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000002477 vacuolizing effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001324 Adrenal atrophy Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 208000000223 Solitary Kidney Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to application of a walnut cake extract in preparation of a medicine for treating kidney injury. Preferably, the kidney injury is an acute kidney injury. The preparation method of the walnut cake extract comprises the following steps: reflux-extracting appropriate amount of semen Juglandis pulp with 10-15 times of 50-80% ethanol solution for 3 times (1-2 hr each time), filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain semen Juglandis pulp extract. The invention effectively expands the development and utilization range of walnut dreg resources, provides reliable data support for developing the walnut dreg resources into functional products with the function of treating kidney injury, and simultaneously provides a new thought and a new method for effectively preventing and treating kidney.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of a walnut cake extract in preparation of a medicine for treating kidney injury.
Background
Acute kidney injury (acute kidney injury, AKI) is a clinically common acute critical illness that severely jeopardizes human health and life, with a high incidence of mortality, and approximately 200 million people die of kidney injury annually worldwide. The renal prognosis of AKI surviving patients is also not optimistic, with 30% -70% of AKI surviving patients progressing to chronic kidney disease and about 17% of patients progressing to end-stage renal failure within 1 year, thus AKI has now become a global public health problem.
At present, no effective drug treatment exists for AKI, so that importance on AKI susceptibility is improved, and effective measures are taken, so that the method is a key for preventing and effectively treating AKI. The modern medicine has very limited prevention and treatment methods for the diseases, and often symptomatic treatment such as body fluid management, maintenance of in vivo environment stability, adjustment of metabolic acidosis and the like is not effective for relieving the occurrence and development of the diseases. The traditional Chinese medicine has a profound theoretical basis and practical experience theory for treating kidney diseases, adopts syndrome differentiation and differentiation type in traditional Chinese medicine treatment, is mostly in the form of compound decoction, has the action advantages of multiple ways and multiple targets, and has obvious effect on improving kidney functions. However, the compound decoction of traditional Chinese medicine generally has the problems of undefined drug effect substance basis and action mechanism, long administration period, slow response speed, uneven effect, inconvenient administration and the like.
Semen Juglandis is a dry mature seed of Juglans regia L. Of Juglandaceae, has Wen Weigan, and has effects of invigorating kidney, warming lung, and moisturizing intestine. As a Chinese medicine with homology of medicine and food, the walnut kernels are rich in nutrient substances such as grease, protein, polyphenol, polysaccharide and the like. The walnut cake is the cake part remained after the walnut kernel removes the oil, has strong antioxidant and anti-inflammatory activities, and can regulate the metabolism of glycolipid. The medicinal examination proves that the walnut cake has the effects of tonifying liver and kidney, resolving hard mass and removing blood stasis. Modern pharmacological researches have found that the walnut cake extract has the effects of resisting inflammation, resisting oxidation, reducing blood pressure, reducing blood fat, reducing blood sugar and the like. However, no report on the prevention and treatment effect of walnut cake on kidney diseases is found at present.
The application establishes western medicine and traditional Chinese medicine syndrome models of acute kidney injury, clarifies the improvement effect of the walnut cake extract on kidney diseases from multiple angles, and discovers the effect of the walnut cake extract (DWPE) on treating kidney injury (especially AKI) for the first time.
In view of this, the present invention has been proposed.
Disclosure of Invention
In order to solve the problem of insufficient medicines which are clinically used at present and can effectively treat kidney injury (especially AKI), the invention provides the application of the walnut cake extract in preparing the medicines for treating kidney injury, and provides a new thought and a new method for effectively preventing and treating kidney diseases.
Specifically, the invention is realized through the following technical schemes:
the invention provides application of a walnut cake extract in preparing a medicament for treating kidney injury.
The walnut cake extract can be prepared by any extraction method known in the field of natural pharmaceutical chemistry.
For example, the method disclosed in "CN 105012382B walnut cake extract, method of making and use thereof" may be employed.
Alternatively, in the above application, the preparation method of the walnut cake extract includes the following steps: reflux-extracting appropriate amount of semen Juglandis pulp with 10-15 times of 50-80% ethanol solution for 3 times (1-2 hr each time), filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain semen Juglandis pulp extract.
Alternatively, in the above application, the preparation method of the walnut cake extract includes the following steps: reflux-extracting appropriate amount of semen Juglandis cake with 12 times of 60% ethanol solution for 3 times each for 1.5 hr, filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain extract of semen Juglandis cake.
Alternatively, in the above use, the kidney injury is acute kidney injury.
Alternatively, in the above-mentioned use, the acute kidney injury is an acute kidney injury caused by diseases such as chemical-induced acute kidney injury, rhabdomyolysis-induced acute kidney injury, ischemia-reperfusion, and aging.
Alternatively, in the above use, the chemical-induced acute kidney injury is drug-induced acute kidney injury.
For example, the chemical or drug may be cisplatin, hydrocortisone, carbon tetrachloride or a contrast agent, or the like.
Alternatively, the acute kidney injury is an acute kidney injury associated with senile dementia.
Alternatively, in the above use, the medicament reduces tubular necrosis, dilation and glycogen deposition, as well as protects and ameliorates kidney tissue morphology damage.
Alternatively, in the above use, the medicament comprises a therapeutically effective amount of the extract of walnut cake and a pharmaceutically acceptable carrier or excipient.
Alternatively, in the above use, the medicament is an oral preparation.
Alternatively, in the above application, the dosage form of the medicament is a tablet, a capsule, a granule, a pill or an oral liquid.
The medicine of the invention can be prepared by adopting a preparation method conventional in the field, and pharmaceutically acceptable auxiliary materials can be optionally added. Regardless of the various variations in the method of preparation, it is within the scope of the present invention. Pharmaceutical forms thereof include solid forms, semi-solid forms, liquid forms, and the like.
Compared with the prior art, the invention has the following beneficial effects:
the invention combines western medicine and traditional Chinese medicine syndrome models of acute kidney injury to clarify the improvement effect of walnut cake extract on kidney diseases from multiple angles. The walnut cake extract is found to have the effect of treating kidney injury (especially AKI) for the first time. The invention effectively expands the development and utilization range of walnut dreg resources, provides reliable data support for developing the walnut dreg resources into functional products with the function of treating kidney injury, and simultaneously provides a new thought and a new method for effectively preventing and treating kidney.
Drawings
Fig. 1: serum BUN and kidney SOD assay results.
Fig. 2: kidney pathological conditions in rats of each group.
Fig. 3: body weight change in each group of rats.
Fig. 4: serum CRE, BUN, T, CORT assay results. Wherein, compared with the Control group, * P＜0.05， ** p is less than 0.01; in comparison with the DYK group, # P＜0.05， ## P＜0.01， ### P＜0.001。
fig. 5: kidney pathological conditions in rats of each group.
Detailed Description
The invention will be further illustrated with reference to specific examples. It should be understood that the detailed description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the invention.
The specific techniques or conditions are not identified in the examples and are described in the literature in this field or are carried out in accordance with the product specifications. The reagents or equipment used were conventional products available for purchase through regular channels, with no manufacturer noted.
The experimental methods in the following examples are conventional methods unless otherwise specified. The test materials used in the examples described below, unless otherwise specified, are all commercially available products.
Example 1: treatment effect of walnut cake extract (DWPE) on acute kidney injury caused by carbon tetrachloride olive oil solution
Kidneys are the main excretory organ of the body and are the main metabolic sites for the excretion of heterologous substances, and are therefore most susceptible to toxic damage. Chemical and drug-induced nephrotoxicity is a major cause of acute kidney injury, as well as a major cause of morbidity and mortality from kidney injury. CCl (CCl) 4 Is an environmental pollutant which can induce the biochemical and oxidative stress parameters of animal blood to change. There are studies showing that CCl 4 Induces lipid peroxidation, protein oxidation and cell membrane damage in the kidney, and therefore CCl is commonly used 4 As an evaluation of anti-renal injury agentThe drug effect of the drug and the inducer of acute kidney injury for exploring the experimental study of pathogenesis of drug-induced kidney injury and the like.
1.1 preparation of walnut cake extract:
taking a proper amount of walnut cake sample, adding 12 times of 60% ethanol solution, reflux-extracting for 3 times each for 1.5 hours, filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain the walnut cake extract.
1.2 experimental method:
60 ICR mice were divided into 3 groups, blank (Control) and model (CCl) 4 ) Walnut meal dosing group (DWPE). The walnut cake administration group (15.6 g/kg; according to Chinese resident diet guidelines, the best 30g walnut kernel is taken by adults each day, the experimental dose is 4 times of the clinical dose) is continuously administrated by gastric lavage for two weeks, the blank and model groups are administrated with equal amount of water, the model group and the walnut cake administration group are administrated by gastric lavage on day 14 for 1 hour and then are intraperitoneally injected with 5% carbon tetrachloride olive oil solution, blood is taken after 24 hours, and kidneys are dissected.
1.3, observing items and methods:
serum urea nitrogen (BUN) and SOD levels: after the blood sample was placed at 4℃overnight, it was centrifuged at 4000r/min for 15min, and the supernatant was collected and tested according to the kit instructions. Adding 9 times of physiological saline into kidney tissue, homogenizing, centrifuging at 4000r/min for 15min, collecting supernatant, and detecting according to kit instructions.
Renal pathological changes: kidney tissue was removed, fixed in 4% paraformaldehyde solution, sectioned in conventional paraffin and HE stained.
The statistical analysis method comprises the following steps: experimental data were processed by Graphpad Prism 7.0 statistical software and measured as mean±sd, and single factor analysis of variance (One-Way ANOVA) was used for the data analysis between groups. P < 0.05 is significant in statistical significance.
1.4 experimental results:
as shown in fig. 1, serum urea nitrogen (BUN) and kidney SOD levels: compared with the Control group, the BUN level in the serum of the Model group is obviously increased, and the SOD level of the kidney is obviously reduced, which indicates that the modeling is successful; the walnut cake extract improved serum BUN and kidney SOD levels after administration compared to Model group.
Renal pathological changes: the kidney tissue structure of the Control group mice is normally arranged compactly, the glomerulus structure is clear, the morphology is normal, and abnormal pathological changes are avoided; CCl (CCl) 4 The kidney tissue structure of the mice is loosely arranged, and glomerular epithelial cells are flattened; after DWPE intervention, pathological changes of kidney tissues are reduced, and glomerular epithelial cell flattening is significantly improved (see fig. 2).
Example 2: treatment of acute kidney injury associated with senile dementia by walnut cake extract (DWPE)
The traditional Chinese medicine syndrome animal model is an essential foundation for revealing the theoretical scientific connotation of traditional Chinese medicine, the kidney-yang deficiency syndrome animal model is the earliest established traditional Chinese medicine syndrome animal model, the etiology and the medicine intervention of kidney-yang deficiency are replicated to achieve the same pathological manifestation as the kidney-yang deficiency, the senile dementia type kidney injury composite model is constructed, and the improvement effect of walnut meal on kidney injury accompanied by aging is explored. Hydrocortisone is an exogenous glucocorticoid, and when a large amount of exogenous glucocorticoid is taken in, corticotropin secreted by pituitary gland is inhibited, so that the secretion of adrenocortical hormone is reduced, adrenal atrophy and kidney metabolic disorder are caused, and kidney failure phenomenon occurs in model animals.
1.1 preparation of walnut cake extract:
taking a proper amount of walnut cake sample, adding 12 times of 60% ethanol solution, reflux-extracting for 3 times each for 1.5 hours, filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain the walnut cake extract.
1.2 experimental method:
91 ICR mice were divided into 7 groups, which were a blank group (Control), a kidney-yang deficiency type senile dementia complex model group (CM), a single senile dementia model group (D-gal), a single kidney-yang deficiency group (DKY), a Guifu rehmannia pill positive drug Group (GDP), a High-dose administration group (High) and a Low-dose administration group (Low), respectively. Injecting physiological saline subcutaneously in the Control group for 1-6 weeks, and irrigating purified water in the stomach for 7-8 weeks; the CM group was subcutaneously injected with D-gal (250 mg/kg) for 1-6 weeks, and hydrocortisone (20 mg/kg) was administered by intragastric administration for 7 and 8 weeks; d-gal groups were given 1, 2 weeks untreated, 3-8 weeks with subcutaneous injections of D-gal (250 mg/kg); DKY group 1-6 weeks of subcutaneous injection of physiological saline, 7, 8 weeks of intragastric administration of hydrocortisone (20 mg/kg); GDP group 1-6 weeks subcutaneously injecting D-gal (250 mg/kg), 7, 8 weeks intragastrically administering hydrocortisone (20 mg/kg), while continuously intragastrically administering corresponding doses of Guifu Dihuang pills for 8 weeks; the High group and the Low group are subcutaneously injected with D-gal (250 mg/kg) for 1-6 weeks, hydrocortisone (20 mg/kg) is administrated by intragastric administration for 7 and 8 weeks, and meanwhile, corresponding crude drugs (15.6 g/kg and 7.8 g/kg) are administrated by preventive intragastric administration, 30g of walnut kernel is optimal for adults daily according to Chinese resident diet guidelines, and the High and Low doses of the experiment are 4 times and 2 times of clinical doses respectively for 8 weeks.
1.3, observing items and methods:
body weight and general status observations: body weight was measured daily starting on day 1 of dosing, animal status was observed weekly, animal general status was observed daily starting on hydrocortisone dosing and recorded.
Serum Corticosterone (CORT), testosterone (T), creatinine (CRE), urea nitrogen (BUN): after the blood sample was placed at 4℃overnight, it was centrifuged at 4000r/min for 15min, and the supernatant was collected and tested according to the kit instructions.
Renal pathological changes: kidney tissue was removed, fixed in 4% paraformaldehyde solution, sectioned in conventional paraffin and HE stained.
The statistical analysis method comprises the following steps: experimental data were processed by Graphpad Prism 7.0 statistical software and measured as mean±sd, and single factor analysis of variance (One-Way ANOVA) was used for the data analysis between groups. P < 0.05 is significant in statistical significance.
1.4 experimental results:
weight change: as shown in FIG. 3, the weight of the Control group mice in 1-8 weeks was in a steady upward trend; the weight of the CM group mice is wholly in an ascending trend during the period of injecting D-gal 1-6 weeks, but the increasing amplitude is lower than that of the Control group mice, and the weight of the CM group mice is in a descending trend after 7-8 weeks of gastric lavage and hydrocortisone; mice in the D-gal group had a steady rise in body weight during 3-8 weeks of D-gal injection; the body weight of the DKY group mice increased gradually for 1-6 weeks, and the body weight decreased significantly during the 7-8 week injection of hydrocortisone. The overall body weight continues to slowly increase during the 1-6 week injection of D-ga1 in the GDP, DWPE_H, and DWPE_L mice, and the body weight tends to decrease after administration of hydrocortisone at week 7.
General state observation: the Control group mice have good mental state within 8 weeks, are Mao Roushun white and clean in hair color and have larger food intake. After injecting D-gal, the mice in CM group and D-gal have slightly less response than the mice in Control group, and the mice in GDP group, DWPE_H group and DWPE_L group have no obvious change during injecting D-gal; after administration of hydrocortisone, the CM group and DKY group mice showed a state of listlessness, binding, skin relaxation, hair dryness, no luster, ingestion, reduced drinking water, increased urine volume, etc., and the GDP group, dwpe_h group and dwpe_l group showed a state of listlessness, binding, ingestion, reduced drinking water, increased urine volume after administration of hydrocortisone at week 7, but gradually recovered at week 8. The GDP group, DWPE_H group and DWPE_L group mice did not develop a dry and dull coat condition, as compared with the CM group mice, with the DWPE_H group mice being the most preferred condition.
Measurement of serum Corticosterone (CORT), testosterone (T), creatinine (CRE), urea nitrogen (BUN): as shown in fig. 4, the CM group and DKY group showed an increase in CRE level (CM group P <0.001, dky group P < 0.01) compared to the Control group, the D-gal group showed an increase trend, and the GDP group, dwpe_h group, and dwpe_l group showed no significant difference, and the CRE level was lower (P < 0.001) than the CM group; the BUN levels of the CM group and the DKY group are obviously increased compared with that of the Control group (the CM group P is less than 0.01, the DKY group P is less than 0.05), the D-gal group is increased, but no obvious difference exists, and the BUN levels of the GDP group, the DWPE_H group and the DWPE_L group are obviously reduced compared with that of the CM group (the GDP group P is less than 0.05, the DWPE_H group P is less than 0.001 and the DWPE_L group P is less than 0.01); the T levels of the CM group and the DKY group are remarkably reduced compared with the Control group (the CM group P is less than 0.01, the DKY group P is less than 0.05), the D-gal has a descending trend, and the T levels of the GDP group, the DWPE_H group and the DWPE_L group are remarkably increased compared with the CM group (the DWPE_H group P is less than 0.001, the GDP group and the DWPE_L group P is less than 0.01); the CORT levels of the CM group and the DKY group are obviously reduced (P is smaller than 0.05) compared with the Control group, the D-gal has a downward trend, the CORT levels of the GDP group, the DWPE_H group and the DWPE_L group are obviously increased compared with the CM group, and the DWPE_H group and the DWPE_L group have obvious differences (P is smaller than 0.05). The walnut cake extract can obviously improve the kidney injury degree, and the improvement effect of the DWPE_H group is better than that of the GDP group and the DWPE L group.
Renal pathological changes: as shown in fig. 5, the Control group has complete kidney tissue, the glomerulus structure is clear, and the tubular ducts are orderly arranged; obvious pathological changes occur in CM group and DKY group, glomerular atrophy, tubular dilation or atrophy, vacuolation of tubular epithelial cells, and inflammatory cell increases; the glomerular tubule of the D-gal group has no obvious lesion, but the inflammatory cells are obviously increased compared with the Control group; while some lesions still exist in the glomeruli and tubules in the GDP, DWPE_H and DWPE_L groups, the morphology of the tubules tends to be normal, the vacuolation is obviously reduced, and inflammatory cells are reduced compared with the CM group.
It will be apparent to those skilled in the art that various modifications and variations can be made to the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention also include such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.
Claims (10)
1. Use of semen Juglandis extract in preparing medicine for treating kidney injury is provided.
2. Use according to claim 1, characterized in that: the preparation method of the walnut cake extract comprises the following steps: reflux-extracting appropriate amount of semen Juglandis pulp with 10-15 times of 50-80% ethanol solution for 3 times (1-2 hr each time), filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain semen Juglandis pulp extract.
3. Use according to claim 2, characterized in that: the preparation method of the walnut cake extract comprises the following steps: reflux-extracting appropriate amount of semen Juglandis cake with 12 times of 60% ethanol solution for 3 times each for 1.5 hr, filtering, concentrating the filtrate, drying under reduced pressure, and pulverizing to obtain extract of semen Juglandis cake.
4. Use according to claim 1, characterized in that: the kidney injury is an acute kidney injury.
5. Use according to claim 4, characterized in that: the acute kidney injury is acute kidney injury caused by chemical substance induced acute kidney injury, acute kidney injury induced by rhabdomyolysis or acute kidney injury caused by ischemia-reperfusion, aging and other diseases.
6. Use according to claim 5, characterized in that: the chemical induced acute kidney injury is drug induced acute kidney injury.
7. Use according to claim 4, characterized in that: the medicament reduces tubular necrosis, dilation and glycogen deposition, and protects and ameliorates morphological damage to kidney tissue.
8. Use according to claim 1, characterized in that: the medicament comprises a therapeutically effective amount of walnut cake extract and a pharmaceutically acceptable carrier or excipient.
9. Use according to claim 1, characterized in that: the medicine is an oral preparation.
10. Use according to claim 9, characterized in that: the dosage form of the medicine is tablets, capsules, granules, pills or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445684.1A CN117298171A (en) | 2023-11-02 | 2023-11-02 | Application of walnut cake extract in preparation of medicine for treating kidney injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311445684.1A CN117298171A (en) | 2023-11-02 | 2023-11-02 | Application of walnut cake extract in preparation of medicine for treating kidney injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117298171A true CN117298171A (en) | 2023-12-29 |
Family
ID=89288442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311445684.1A Pending CN117298171A (en) | 2023-11-02 | 2023-11-02 | Application of walnut cake extract in preparation of medicine for treating kidney injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117298171A (en) |
-
2023
- 2023-11-02 CN CN202311445684.1A patent/CN117298171A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112791160A (en) | Uric acid-reducing anti-inflammatory analgesic medicinal and edible traditional Chinese medicine composition and preparation method thereof | |
| CN114209810B (en) | Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease | |
| JP4413013B2 (en) | A kind of anti-rheumatic preparation and its production method | |
| CN1709454A (en) | Chinese medicine formulation for treating arthrolithiasis, and its preparing method | |
| CN102872334B (en) | Application of medicinal composition for treating diabetes mellitus | |
| CN114073731A (en) | A Chinese medicinal composition for treating abdominal pain and diarrhea | |
| CN111329950A (en) | Application of traditional Chinese medicine composition and preparation thereof in preparation of medicine for treating acute lung injury | |
| WO2023088488A1 (en) | Traditional chinese medicine composition for preventing and treating brain diseases, preparation method therefor, and application thereof | |
| CN117298171A (en) | Application of walnut cake extract in preparation of medicine for treating kidney injury | |
| CN100333758C (en) | Gout resisting Chinese medicine composition and its prepn process | |
| CN102133273A (en) | Traditional Chinese medicine lipid-lowing and aperient capsule and preparation method thereof | |
| CN114272295B (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| JP7157253B2 (en) | Chinese herbal composition for enema constipation, its preparation method and its use | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN102430039A (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN114246910A (en) | Traditional Chinese medicine composition for treating gout and application thereof | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN116350728B (en) | Traditional Chinese medicine composition for reducing uric acid and/or resisting inflammation and relieving pain and application thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN116370548B (en) | Traditional Chinese medicine composition with effect of improving polycystic ovarian syndrome and preparation method and application thereof | |
| CN114767803B (en) | Dendrobium officinale traditional Chinese medicine composition for down-regulating kidney PDZK1 protein to prevent hyperuricemia, and preparation method and application thereof | |
| CN113368209B (en) | New use of QIZHI Capsule in preparing medicine for treating essential hypertension | |
| CN113546116B (en) | Preparation method of traditional Chinese medicine extract with blood pressure lowering effect | |
| CN111297887B (en) | Preparation method and application of liver-protecting active component of Yunnan ginseng | |
| CN106619972A (en) | Hirsutella hepiali chen et shen mycelium powder hypoglycemic capsule and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |